JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265118

Human APTX (Aprataxin) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

APTX KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 321 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human APTX (Aprataxin) knockout HeLa cell line (AB265118)
  • WB

Lab

Western blot - Human APTX (Aprataxin) knockout HeLa cell line (AB265118)

False colour image of Western blot : Anti-Aprataxin antibody staining at 1/500 dilution shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution shown in red. In Western blot ab154413 was shown to bind specifically to Aprataxin. A band was observed at 41 kDa in wild-type HeLa cell lysates with no signal observed at this size in APTX CRISPR-Cas9 edited cell line ab265118 (CRISPR-Cas9 edited cell lysate ab257837). The band observed in the CRISPR-Cas9 edited lysate lane below 41 kDa is likely to represent a truncated form of Aprataxin. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image wild-type and APTX CRISPR-Cas9 edited HeLa cell lysates were analysed. First samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °. Blots were washed four times in TBS-T incubated with secondary antibodies for 1 h at room temperature washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

Lanes 1, 2 and 4:

Western blot - Anti-Aprataxin antibody (<a href='/en-us/products/primary-antibodies/aprataxin-antibody-ab154413'>ab154413</a>) at 1/500 dilution

Lane 3:

Western blot - Anti-Aprataxin antibody (<a href='/en-us/products/primary-antibodies/aprataxin-antibody-ab154413'>ab154413</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

APTX CRISPR-Cas9 edited HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human APTX (Aprataxin) knockout HeLa cell line (ab265118)

Lane 3:

HepG2 cell lysate at 20 µg

Lane 4:

Saos-2 cell lysate at 20 µg

Predicted band size: 41 kDa

Observed band size: 41 kDa

false

Sanger Sequencing - Human APTX (Aprataxin) knockout HeLa cell line (AB265118)
  • Sanger seq

Unknown

Sanger Sequencing - Human APTX (Aprataxin) knockout HeLa cell line (AB265118)

Homozygous : 321 bp insertion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 321 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265118-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265118-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265118 Human APTX (Aprataxin) knockout HeLa cell line", "number":"AB265118-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265118-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265118 Human APTX (Aprataxin) knockout HeLa cell line", "number":"AB265118-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265118-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265118-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265118 Human APTX (Aprataxin) knockout HeLa cell line", "number":"AB265118-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265118-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265118 Human APTX (Aprataxin) knockout HeLa cell line", "number":"AB265118-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
APTX
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Aprataxin also known as APTX is a protein involved in DNA repair. It belongs to the histidine triad superfamily and has a molecular mass of approximately 40 kDa. The protein is expressed in various tissues including the brain liver and kidney. Aprataxin's main role involves the repair of DNA strand breaks by removing abnormal DNA termini. It restores DNA integrity which is critical for maintaining cellular functions.
Biological function summary

Aprataxin plays an important role in the DNA single-strand break repair processes. It functions within the DNA repair machinery often as part of complexes with other repair proteins. This protein mainly interacts with other partners like XRCC1 and PARP1 to facilitate accurate DNA repair. Its interaction ensures proper response to DNA damage safeguarding the genome's stability and function.

Pathways

Aprataxin is integrally connected to the base excision repair (BER) pathway and the DNA damage response pathway. These pathways are fundamental mechanisms for repairing damaged DNA and preserving cell viability. Within these pathways Aprataxin closely collaborates with related proteins like XRCC1 and PARP1. These associations highlight Aprataxin's role in ensuring the efficiency and success of DNA repair processes.

Mutations or malfunctions in Aprataxin are linked to neurological conditions such as ataxia with oculomotor apraxia 1 (AOA1) and spinocerebellar ataxia with axonal neuropathy (SCAN1). These disorders are marked by progressive loss of movement coordination and peripheral neuropathy. In the context of these diseases Aprataxin interacts with proteins involved in neuronal maintenance and protection such as TDP-43 and p53. Disruptions in such interactions often result in the observed pathological manifestations.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com